Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 10/20 | 0.44 |
| ▸ | CPA3 | P15088 | 3/20 | 0.41 |
| ▸ | CPA1 | P15085 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203402 | 0.89 | PPARG (0.46) | MMEITGA4ITGB7 | |
| Lithium Ion SCHEMBL6804295 | 0.88 | MME (0.39) | CYP1A2MMEITGA4ITGB7OPRM1 | |
| SCHEMBL6203424 | 0.85 | PPARG (0.41) | MMEITGA4ITGB7 | |
| SCHEMBL6797773 | 0.79 | SOAT2 (0.48) | MME | |
| SCHEMBL1813952 | 0.74 | GAA (0.50) | OPRM1 | |
| SCHEMBL6984579 | 0.73 | HSD11B1 (0.40) | MME | |
| SCHEMBL6801610 | 0.73 | SOAT2 (0.49) | MME | |
| SCHEMBL6253853 | 0.72 | FPR2 (0.48) | ITGA4ITGB7 | |
| SCHEMBL15863115 | 0.69 | GRIN1 (0.47) | OPRM1 | |
| SCHEMBL6249722 | 0.69 | OPRM1 (0.56) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | CYP1A2 952/4885MME 282/4885CPA3 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.